Clovis Oncology, Inc. (CLVS) is Sphera Funds Management LTD.’s 10th Largest Position
Sphera Funds Management LTD. boosted its position in Clovis Oncology, Inc. (NASDAQ:CLVS) by 69.9% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 158,000 shares of the biopharmaceutical company’s stock after purchasing an additional 65,000 shares during the period. Clovis Oncology comprises approximately 1.9% of Sphera Funds Management LTD.’s holdings, making the stock its 10th largest position. Sphera Funds Management LTD. owned about 0.32% of Clovis Oncology worth $13,019,000 at the end of the most recent quarter.
A number of other large investors have also recently made changes to their positions in CLVS. Capital Analysts LLC acquired a new stake in Clovis Oncology in the third quarter valued at about $111,000. Phocas Financial Corp. acquired a new stake in Clovis Oncology in the second quarter valued at about $112,000. Cypress Capital Management LLC WY lifted its position in Clovis Oncology by 272.7% in the third quarter. Cypress Capital Management LLC WY now owns 2,050 shares of the biopharmaceutical company’s stock valued at $169,000 after purchasing an additional 1,500 shares during the period. Advisors Asset Management Inc. lifted its position in Clovis Oncology by 160.7% in the second quarter. Advisors Asset Management Inc. now owns 1,895 shares of the biopharmaceutical company’s stock valued at $177,000 after purchasing an additional 1,168 shares during the period. Finally, Commonwealth Equity Services Inc acquired a new stake in Clovis Oncology in the third quarter valued at about $239,000.
In other news, insider Gillian C. Ivers-Read sold 3,000 shares of the business’s stock in a transaction on Monday, October 16th. The shares were sold at an average price of $84.54, for a total transaction of $253,620.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders have sold a total of 9,000 shares of company stock valued at $653,220 over the last three months. Corporate insiders own 12.50% of the company’s stock.
ILLEGAL ACTIVITY WARNING: This story was first reported by Daily Political and is owned by of Daily Political. If you are accessing this story on another domain, it was illegally stolen and republished in violation of United States & international trademark & copyright laws. The original version of this story can be accessed at https://www.dailypolitical.com/2017/11/23/clovis-oncology-inc-clvs-is-sphera-funds-management-ltd-s-10th-largest-position.html.
Shares of Clovis Oncology, Inc. (NASDAQ CLVS) traded up $0.35 during trading on Thursday, hitting $61.52. The company had a trading volume of 1,046,900 shares, compared to its average volume of 1,848,898. The company has a debt-to-equity ratio of 0.94, a current ratio of 3.19 and a quick ratio of 3.16. Clovis Oncology, Inc. has a 1 year low of $33.23 and a 1 year high of $99.45.
Clovis Oncology (NASDAQ:CLVS) last issued its quarterly earnings data on Wednesday, November 1st. The biopharmaceutical company reported ($1.24) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.18) by ($0.06). Clovis Oncology had a negative return on equity of 122.06% and a negative net margin of 947.47%. The company had revenue of $16.81 million for the quarter, compared to analyst estimates of $21.12 million. During the same quarter in the prior year, the firm earned ($1.70) earnings per share. analysts forecast that Clovis Oncology, Inc. will post -7.63 EPS for the current fiscal year.
A number of equities research analysts have recently issued reports on CLVS shares. Cann reiterated a “hold” rating on shares of Clovis Oncology in a research report on Monday, July 31st. J P Morgan Chase & Co reiterated an “overweight” rating on shares of Clovis Oncology in a research report on Tuesday, August 1st. BidaskClub upgraded shares of Clovis Oncology from a “buy” rating to a “strong-buy” rating in a research report on Wednesday, August 2nd. Bank of America Corporation reiterated a “buy” rating on shares of Clovis Oncology in a research report on Thursday, August 3rd. Finally, Morgan Stanley reiterated an “overweight” rating and set a $93.00 price target on shares of Clovis Oncology in a research report on Thursday, August 10th. Eight analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average price target of $86.15.
About Clovis Oncology
Clovis Oncology, Inc is a biopharmaceutical company focused on acquiring, developing and commercializing anti-cancer agents in the United States, Europe and other international markets. The Company’s product candidates include Rociletinib, Rubraca (Rucaparib) and Lucitanib. Rucaparib is an oral, small molecule poly adenosine diphosphate (ADP)-ribose polymerase (PARP) inhibitor of PARP1, PARP2 and PARP3 approved as a monotherapy for the treatment of patients with deleterious breast cancer (BRCA) (human genes associated with the repair of damaged deoxyribonucleic acid (DNA)) mutation (germline and/or somatic) associated advanced ovarian cancer.
Receive News & Ratings for Clovis Oncology Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clovis Oncology Inc. and related companies with MarketBeat.com's FREE daily email newsletter.